MNEXSPIKE DIN 02561433
Status: Approved
Holder: MODERNA BIOPHARMA CANADA CORPORATION
Health Canada record
| Active ingredient(s) | *SARSCOV2 S-PROTEIN NTD-RBD SUBDOMAINS MRNA, 5'(M7G-5'-PPP-5'-GM), 3'POLYA 10 MCG |
|---|---|
| Dosage form | Dispersion |
| Route | Intramuscular |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J07BN01 COVID-19, RNA-BASED VACCINE |
| Original market date | |
| Current status date | 29-Sep-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Moderna Biopharma Canada Corporation — licence 3-002801, currently licensed, last inspection rating C (2024-06-10).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36079 | 2025-09-29 | New Drug Submission (NDS) |